spiraprilat has been researched along with lisinopril in 2 studies
| Studies (spiraprilat) | Trials (spiraprilat) | Recent Studies (post-2010) (spiraprilat) | Studies (lisinopril) | Trials (lisinopril) | Recent Studies (post-2010) (lisinopril) |
|---|---|---|---|---|---|
| 20 | 7 | 0 | 2,210 | 648 | 491 |
| Protein | Taxonomy | spiraprilat (IC50) | lisinopril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.0021 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.287 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0012 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.0012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennion, C; Brown, RC; Cook, AR; Manners, CN; Payling, DW; Robinson, DH | 1 |
| Baum, T; Gold, EH; McNamara, P; Neustadt, BR; Smith, EM; Swiss, GF; Sybertz, EJ | 1 |
2 other study(ies) available for spiraprilat and lisinopril
| Article | Year |
|---|---|
Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bile; Drug Design; Indicators and Reagents; Male; Metabolic Clearance Rate; Models, Molecular; Molecular Conformation; Molecular Structure; Rats; Structure-Activity Relationship; Thiadiazoles; X-Ray Diffraction | 1991 |
Angiotensin converting enzyme inhibitors: spirapril and related compounds.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Chemical Phenomena; Chemistry; Dogs; Enalapril; Male; Phenylbutyrates; Rats; Rats, Inbred Strains; Spiro Compounds | 1989 |